Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 6/20 | 0.55 |
| ▸ | HTR2C known ✓ | P28335 | 6/20 | 0.55 |
| ▸ | HTR2B known ✓ | P41595 | 6/20 | 0.55 |
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 0.55 |
| ▸ | KMT2A known ✓ | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 known ✓ | O00255 | 3/20 | 0.54 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | CCR2 | P41597 | 1/20 | 0.50 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL5945716 | 1.00 | SIGMAR1 (0.74) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| Fumaric Acid SCHEMBL7488785 | 1.00 | SIGMAR1 (0.74) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| Fumaric Acid SCHEMBL7488780 | 1.00 | SIGMAR1 (0.74) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| Bicarbonate SCHEMBL21981463 | 0.90 | SIGMAR1 (0.85) | SIGMAR1KMT2AMEN1ALDH1A1CYP2C9 | |
| Acetic Acid SCHEMBL7452259 | 0.87 | SIGMAR1 (0.79) | SIGMAR1KMT2AMEN1ALDH1A1CYP2C9 | |
| Urea SCHEMBL6942597 | 0.87 | SIGMAR1 (0.79) | SIGMAR1KMT2AMEN1ALDH1A1CYP2C9 | |
| SCHEMBL6138636 | 0.86 | SIGMAR1 (1.00) | SIGMAR1KMT2AMEN1ALDH1A1CYP2C9 | |
| SCHEMBL83548 | 0.86 | SIGMAR1 (1.00) | SIGMAR1KMT2AMEN1ALDH1A1CYP2C9 | |
| SCHEMBL276363 | 0.86 | SIGMAR1 (1.00) | SIGMAR1KMT2AMEN1ALDH1A1CYP2C9 | |
| SCHEMBL152631 | 0.86 | SIGMAR1 (1.00) | SIGMAR1KMT2AMEN1ALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370446-B1 | 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-B]PYRIDIN-4-YL)IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES,PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2015-11-25 | — | — | EP | disclosed |
| US-8546395-B2 | 6-cycloamino-3-(1H-pyrrolo[2,3-b]pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| US-20120010208-A1 | 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-b]PYRIDIN-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-01-12 | — | — | US | disclosed |
| CN-102232079-A | 6-cycloamino-3-(1h-pyrrolo[2, 3-b]pyridin-4-yl)imidazo[1, 2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof | SANOFI AVENTIS | 2011-11-02 | — | — | CN | disclosed |
| EP-2370446-A1 | 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-B]PYRIDIN-4-YL)IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES,PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010063929-A1 | 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-B]PYRIDIN-4-YL)IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | WO | disclosed |
| US-20060217394-A1 | Treatment of anhedonia | SILVAN S. TOMKINS INSTITUTE, INC. | 2006-09-28 | — | — | US | disclosed |
| WO-2006091725-A1 | TREATMENT OF ANHEDONIA | THE SILVAN S. TOMKINS INSTITUTE (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010208-A1 | 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-b]PYRIDIN-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CBR3, CBR1, CNR1 | HTR2A 1486/4885HTR2C 712/4885HTR2B 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.